Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer

BACKGROUND: The phosphatidylinositol-3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is commonly deregulated in human cancer, hence many PI3K and mTOR inhibitors have been developed and have now reached clinical trials. Similarly, CDKs have been investigated as cancer drug targets. METHOD...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Br J Cancer
Main Authors: Beale, Gary, Haagensen, Emma J, Thomas, Huw D, Wang, Lan-Zhen, Revill, Charlotte H, Payne, Sara L, Golding, Bernard T, Hardcastle, Ian R, Newell, David R, Griffin, Roger J, Cano, Celine
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2016
נושאים:
Translational Therapeutics
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5023777/
https://ncbi.nlm.nih.gov/pubmed/27529512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.238
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים